Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lia Gore

Showing results (81-90 of 119) with videos related to

Pageof 12
Sort By:
Cancer|December 22, 2017
Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131Wanda L Salzer, Michael J Burke, Meenakshi Devidas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium studyRochelle Bagatell, Lia Gore, Merrill J Egorin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2024
Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group StudySarah Alexander, John A Kairalla, Sumit Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2022
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621Maureen M O'Brien, Lingyun Ji, Nirali N Shah, et al.
Pediatric Blood & Cancer|April 1, 2018
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemiaAndrew E Place, Yana Pikman, Kristen E Stevenson, et al.
Pediatric Blood & Cancer|November 20, 2014
Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology GroupWanda L Salzer, Tamekia L Jones, Meenakshi Devidas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2008
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancersAlex A Adjei, Roger B Cohen, Wilbur Franklin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2Jennifer L Spratlin, Roger B Cohen, Matthew Eadens, et al.
Pediatric Blood & Cancer|May 26, 2017
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium studyMargaret E Macy, Mark W Kieran, Susan N Chi, et al.
Leukemia|February 24, 2021
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
Cancer|December 22, 2017
Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131Wanda L Salzer, Michael J Burke, Meenakshi Devidas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium studyRochelle Bagatell, Lia Gore, Merrill J Egorin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2024
Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group StudySarah Alexander, John A Kairalla, Sumit Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2022
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621Maureen M O'Brien, Lingyun Ji, Nirali N Shah, et al.
Pediatric Blood & Cancer|April 1, 2018
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemiaAndrew E Place, Yana Pikman, Kristen E Stevenson, et al.
Pediatric Blood & Cancer|November 20, 2014
Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology GroupWanda L Salzer, Tamekia L Jones, Meenakshi Devidas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2008
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancersAlex A Adjei, Roger B Cohen, Wilbur Franklin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2Jennifer L Spratlin, Roger B Cohen, Matthew Eadens, et al.
Pediatric Blood & Cancer|May 26, 2017
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium studyMargaret E Macy, Mark W Kieran, Susan N Chi, et al.
Leukemia|February 24, 2021
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Pageof 12